Talon Therapeutics, Inc.' Recently Approved Marqibo Presented at 2012 Chemotherapy Foundation Symposium

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON), a biopharmaceutical company dedicated to developing leading oncology products, today announced that data from its pivotal Phase 2 RALLY trial of Marqibo was presented by Dr. Dan Douer, Leader of the Acute Lymphoblastic Leukemia (ALL) Program at Memorial Sloan-Kettering, at the Chemotherapy Foundation Symposium in New York. Marqibo received accelerated approval from the U.S. Food and Drug Administration on Aug. 9, 2012 for the treatment of adult patients with Ph- ALL in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.